This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

XOMA Corporation (XOMA)

Q2 2012 Earnings Call

August 7, 2012 4:30 pm ET


Ashleigh Barreto – Investor Relations

John W. Varian – Chief Executive Officer

Paul D. Rubin – Senior Vice President, Research and Development and Chief Medical Officer

Fred Kurland – Vice President-Finance and Chief Financial Officer


Adnan Butt – RBC Capital Markets

Matthew Kaplan – Ladenburg Thalmann & Co.

Liana Moussatos – Wedbush Securities

Thomas Yip – MLV & Co.

Whitney Ijem – Canaccord Genuity Inc.

Joseph Pantginis – Roth Capital Partners



Good afternoon, ladies and gentlemen, and welcome to XOMA Corporation’s Second Quarter 2012 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call may be recorded.

I would now like to turn the call over to your host for today, Ashleigh Barreto, Investor Relations at XOMA. You may proceed.

Ashleigh Barreto

Thank you, operator. Good afternoon and welcome to XOMA Corporation’s Second quarter 2012 financial results and corporate update conference call. On our call today are John Varian, Chief Executive Officer; Dr. Paul Rubin, Senior Vice President, Research and Development and Chief Medical Officer; and Fred Kurland, Chief Financial Officer.

Certain statements made during this call including but limited to statement related to anticipated timing of initiation and completion of clinical trials, anticipated size of clinical trials, continued sales of approved products, regulatory approval of unapproved product candidates and anticipated restructuring charges, sufficiency of our cash resources, and anticipated levels of cash utilization or otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,835.67 +23.48 0.13%
S&P 500 2,088.15 -0.99 -0.05%
NASDAQ 5,106.2780 +3.47 0.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs